- In Vitro Models for Drug Screening
Drug discovery is a process where a new drug or medications are discovered and aims to identify a compound therapeutically useful in curing and treating disease. It includes a wide range of scientific divisions, including biology, chemistry, and pharmacology.
This process associates with the identification of candidates, synthesis, characterization, validation, optimization, screening, and assays for therapeutic efficacy.
The three major phases are:
- Formulation,
- Delivery,
- Packaging Development
Drug Development Phases includes:
- Phase 1: Discovery and Development.
- Phase 2: Preclinical Research.
- Phase 3: Clinical Research.
- Phase 4: FDA Review.
- Phase 5: FDA Post-Market Safety Monitoring.
Drug screening is a process where potential drugs are identified and optimized before the selection of a candidate drug to progress to clinical trials. It can involve screening large volumes of chemicals for a particular biological activity in high-throughput screening assays.
Drug screening mainly includes In-vivo and In-vivo models for drug screening
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Andreas M Papas
Antares Health Products, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian FederationSubmit your abstract Today
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G Protein-Coupled Receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Emerging formulation and delivery applications of Vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Macitentan/Tadalafil Combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : The promise of nanotechnology in Personalized & Precision Medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Navigating the regulatory landscape for nanotechnology-based pharmaceuticals: challenges and strategies for harmonization
Srividya Narayanan, Northeastern University, United States
Title : Strategies for addressing latent HIV-1 microglial cell reservoirs in adolescents and young adults with Neuro-HIV: Steps towards an HIV cure
Aarti V Belgamwar, Shri Vile Parle Kelvani Mandal’s Institute of Pharmacy, India